Mobocertinib (succinate)

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research[1][2].

Product Specifications

CAS Number

[2389149-74-8]

Product Name Alternative

TAK-788 (succinate) ; AP32788 (succinate)

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mobocertinib-succinate.html

Purity

99.83

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C.O=C(O)CCC(O)=O

Molecular Formula

C36H45N7O8

Molecular Weight

703.78

References & Citations

[1]Gonzalvez F, et al. Mobocertinib (TAK-788) : A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Jul;11 (7) :1672-1687. |[2]an H, et al. Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Res. 2021 Oct 15;81 (20) :5311-5324.